Fmr Llc ownership in NB3 / Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

DE ˙ DB ˙ US64125C1099

134,65 € ↑0,30 (0,22%)

2026-06-03
DEL PRIS

Security	DE:NB3 / Neurocrine Biosciences, Inc.
Institution	Fmr Llc
Latest Disclosed Ownership	3,780,076 shares
Ownership	3.99%

2021-08-10 - Fmr Llc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,780,076 shares of Neurocrine Biosciences, Inc. (DE:NB3). This represents 3.994 percent ownership of the company. In their previous filing dated 2021-02-08 , Fmr Llc had reported owning 8,436,629 shares, indicating a decrease of -55.19 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2021-08-10	2021-08-10	13G/A	8,436,629	3,780,076	-55.19	3.99	-55.73
2021-02-08	2021-02-08	13G/A	7,431,373	8,436,629	13.53	9.02	11.96
2020-02-07	2020-02-07	13G/A	8,470,788	7,431,373	-12.27	8.06	-12.28
2019-12-10	2019-12-10	13G/A	13,097,329	8,470,788	-35.32	9.19	-36.34
2019-02-13	2019-02-13	13G/A	13,273,956	13,097,329	-1.33	14.43	-3.79
2018-02-13	2018-02-13	13G/A	12,950,296	13,273,956	2.50	15.00	0.62
2017-02-14	2017-02-14	13G/A	12,929,451	12,950,296	0.16	14.91	-0.61
2016-02-12	2016-02-12	13G/A		12,929,451		15.00
2015-02-13	2015-02-13	13G/A		11,400,773		15.00
2014-02-14	2014-02-14	13G/A		10,101,509		15.00
2013-02-14	2013-02-14	13G/A		9,957,703		15.00
2012-02-14	2012-02-14	13G/A		8,287,661		15.00

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	154,867	84,394	119.75	20,402	104.12	0.0002
2026-02-17	2025-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	70,473	-1,868	-2.58	9,995	-1.58	0.0005
2025-11-13	2025-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	72,341	-182,503	-71.61	10,155	-68.30	0.0005
2025-08-14	2025-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	254,844	158,926	165.69	32,031	201.95	0.0018
2025-05-12	2025-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	95,918	-43,744	-31.32	10,609	-44.35	0.0007
2025-02-13	2024-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	139,662	-106,444	-43.25	19,064	-32.77	0.0011
2024-11-13	2024-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	246,106	-95,723	-28.00	28,356	-39.74	0.0017
2024-08-13	2024-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	341,829	109,310	47.01	47,060	46.75	0.0030
2024-05-13	2024-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	232,519	-32,033	-12.11	32,069	-8.00	0.0022
2024-02-13	2023-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	264,552	242,547	1,102.24	34,857	1,308.36	0.0027
2023-11-13	2023-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	22,005	12,420	129.58	2,476	174.09	0.0002
2023-08-11	2023-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	9,585	-22,990	-70.58	904	-72.61	0.0001
2023-08-11	2023-03-31	13F/A-1	NEUROCRINE BIOSCIENCES	COM	64125C109	32,575	-753,973	-95.86	3,297	-96.49	0.0003
2023-05-11	2023-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	32,575	-753,973		3,297		0.0001
2023-02-13	2022-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	786,548	443,868	129.53	93,945	158.12	0.0093
2022-11-10	2022-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	342,680	109,175	46.75	36,396	59.90	0.0038
2022-08-12	2022-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	233,505	-6,156	-2.57	22,762	1.31	0.0023
2022-05-13	2022-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	239,661	-434,980	-64.48	22,468	-60.90	0.0018
2022-02-14	2021-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	674,641	-2,790,506	-80.53	57,459	-82.71	0.0042
2022-02-14	2021-09-30	13F/A-1	NEUROCRINE BIOSCIENCES	COM	64125C109	3,465,147	-763,211	-18.05	332,343	-19.24	0.0264
2021-11-15	2021-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,465,147	-763,211		332,343		0.0264
2021-08-13	2021-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	4,228,358	-2,873,730	-40.46	411,505	-40.42	0.0322
2021-05-14	2021-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	7,102,088	-1,254,990	-15.02	690,678	-13.78	0.0590
2021-02-08	2020-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	8,357,078	-346,668	-3.98	801,027	-4.29	0.0713
2020-11-13	2020-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	8,703,746	337,012	4.03	836,951	-18.01	0.0846
2020-08-24	2020-06-30	13F/A-1	NEUROCRINE BIOSCIENCES	COM	64125C109	8,366,734	1,083,313	14.87	1,020,742	61.92	0.1122
2020-08-13	2020-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	8,366,734	1,083,313		1,020,742		25,076.6439
2020-05-14	2020-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	7,283,421	-29,215	-0.40	630,380	-19.80	0.0873
2020-02-07	2019-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	7,312,636	-1,316,144	-15.25	786,035	1.09	0.0867
2019-11-13	2019-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	8,628,780	-577,016	-6.27	777,539	0.04	0.0933
2019-08-13	2019-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	9,205,796	-1,231,257	-11.80	777,245	-15.47	0.0908
2019-05-13	2019-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	10,437,053	-2,579,538	-19.82	919,505	-1.08	0.1102
2019-02-13	2018-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	13,016,591	-473,255	-3.51	929,515	-43.96	0.1273
2018-11-09	2018-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	13,489,846	38,645	0.29	1,658,578	25.51	0.1866
2018-08-10	2018-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	13,451,201	60,325	0.45	1,321,446	18.99	0.1560
2018-05-14	2018-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	13,390,876	117,108	0.88	1,110,506	7.83	0.1318
2018-02-12	2017-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	13,273,768	40,738	0.31	1,029,912	27.01	0.1207
2017-11-13	2017-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	13,233,030	22,007	0.17	810,920	33.44	0.0980
2017-08-29	2017-06-30	13F/A-1	NEUROCRINE BIOSCIENCES	COM	64125C109	13,211,023	1,180,874	9.82	607,707	16.66	0.0755
2017-08-11	2017-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	13,211,023	1,180,874		607,707
2017-05-11	2017-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	12,030,149	-919,926	-7.10	520,905	3.94	0.0662
2017-02-10	2016-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	12,950,075	-51,727	-0.40	501,168	-23.88	0.0670
2016-11-14	2016-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	13,001,802	304,995	2.40	658,412	14.10	0.0877
2016-08-11	2016-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	12,696,807	-270,800	-2.09	577,070	12.52	0.0788
2016-05-16	2016-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	12,967,607	38,464	0.30	512,869	-29.88	0.0710
2016-02-12	2015-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	12,929,143	48,165	0.37	731,401	42.70	0.0984
2015-11-10	2015-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	12,880,978	1,819,038	16.44	512,534	-2.99	0.0730
2015-08-25	2015-06-30	13F/A-1	NEUROCRINE BIOSCIENCES	COM	64125C109	11,061,940	-828,214	-6.97	528,318	11.89	0.0677
2015-08-13	2015-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	11,061,940			528,318
2015-05-14	2015-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	11,890,154	489,381	4.29	472,158	85.38	0.0601
2015-02-17	2014-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	11,400,773	12,863	0.11	254,693	42.73	0.0331
2014-11-14	2014-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	11,387,910	12,515	0.11	178,449	5.71	0.0242
2014-08-14	2014-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	11,375,395	76,809	0.68	168,811	-7.20	0.0226
2014-05-15	2014-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	11,298,586	1,197,077	11.85	181,907	92.80	0.0253
2014-02-13	2013-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	10,101,509	42,167	0.42	94,348	-17.14	0.0133
2013-11-14	2013-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	10,059,342	600,130	6.34	113,871	-10.03	0.0174
2013-09-24	2013-06-30	13F/A-1	NEUROCRINE BIOSCIENCES	COM	64125C109	9,459,212	9,459,212		126,564		0.0207
2013-08-14	2013-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	9,459,212			126,564		0.0207

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.